Skip to content
OpenCapital
Get started

MoonLake Immunotherapeutics MLTX EPS (Basic)

EPS (Basic) at other companies

Eli Lilly logo
Eli LillyLLY
$8.27+169%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$1.84-43.8%
Opko Health logo
Opko HealthOPK
-$0.07+30.0%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$1.82+49.7%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$0.26+52.9%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$0.71+13.4%

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.49B-45.9%
Enterprise value$1.29B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's EPS (basic)?
MoonLake Immunotherapeutics (MLTX) reported EPS (basic) of -$0.98 in Q1 2026.
How has MoonLake Immunotherapeutics's EPS (basic) changed year-over-year?
MoonLake Immunotherapeutics's EPS (basic) decreased by 55.6% year-over-year, from -$0.63 to -$0.98.
What is the long-term trend for MoonLake Immunotherapeutics's EPS (basic)?
Over 3 years (2022 to 2025), MoonLake Immunotherapeutics's EPS (basic) has grown at a -5.8% compound annual growth rate (CAGR), from -$4.21 to -$3.52.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.